Close Menu

NEW YORK – New study results have confirmed that advanced melanoma patients treated with a combination of molecularly targeted drugs appear to see significant benefit from this approach compared to what would be expected based on data from older studies of non-targeted treatment.

The new evidence, from a five-year outcomes analysis of a prospective clinical trial, adds to growing affirmation of the positive impact of precision medicine, at least for certain subsets of cancer patients. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.


This webinar will address how two molecular laboratories are implementing tertiary analysis software to improve their precision oncology workflows.


This webinar will review how liquid biopsy can be considered as an alternative and non-invasive method to tissue biopsy for cancer molecular characterization.

Sponsored by

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  


This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.